Why IMU is a multi multi bagger, page-11356

"And in the end, Viralytics' only drug candidate (Cavatak) didn't make it to commercialisation, so in retrospect a good outcome for shareholders."

That's true dyeman.

Although the conspiracy theory is that Merck bought it to stop Bristol MS from using it to boost their drug, which was Merck's competition.

In hindsight it was a good price that we get for Viralytics. $500m with just one drug, which seemed to improve the performance of a few others.

If you look at what ptx has, for example. Two techs that drastically improve pretty much every cancer drug out there, the next generation CAR-T technology (developed by the original inventors and Oxford Uni) and an Orphan drug that is achieving 2x plus better results than current drugs. And ptx have an enterprise value of only $60m.

Then there's imu. ok, the mc is $834m, but so many drugs and pipelines, plus over $150m in cash.

And cf33, which might well be THE cancer cure.